Literature DB >> 15479505

Case fatality and health care costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen University Hospital, France.

F Basuyau1, V Josset, V Merle, P Czernichow.   

Abstract

Vital prognosis in HIV-infected patients has been improved by new therapies, leading to an increase in treatment and outpatient costs but lower inpatient care costs. The aim of the study was to compare the health care costs between 1992-1996 (first half) and 1996-2000 (second half) in HIV-infected patients at Rouen University Hospital. Hospitalization costs (including inpatient and outpatient care), infectious complication treatment and antiretroviral therapy costs were evaluated from a National Health Insurance viewpoint. Between 1992 and 2000, 1212 patients were admitted at least once. Total expenditure increased between the two periods from 13,660 Euro to 27,567 Euro, i.e., a two-fold increase. During the same period, 125 deaths were avoided, and 3602 years of life were gained. The cost of one avoided death was 108,320 Euro and the cost per life-year gained was 3776 Euro.

Entities:  

Mesh:

Year:  2004        PMID: 15479505     DOI: 10.1177/095646240401501009

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

1.  Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Authors:  Caroline E Sloan; Karen Champenois; Philippe Choisy; Elena Losina; Rochelle P Walensky; Bruce R Schackman; Faiza Ajana; Hugues Melliez; A D Paltiel; Kenneth A Freedberg; Yazdan Yazdanpanah
Journal:  AIDS       Date:  2012-01-02       Impact factor: 4.177

2.  Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.

Authors:  Juan Oliva-Moreno; Julio López-Bastida; Pedro Serrano-Aguilar; Lilisbeth Perestelo-Pérez
Journal:  Eur J Health Econ       Date:  2010-01-05

3.  The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.

Authors:  Julio Lopez-Bastida; Juan Oliva-Moreno; Lilisbeth Perestelo-Perez; Pedro Serrano-Aguilar
Journal:  BMC Health Serv Res       Date:  2009-03-30       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.